10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||||||||||||||
| ||||||||||||||
|
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2016 | |||
Consolidated Statement of Income | |||
Period Ending Dec 31, 2016 10-K (Filed: Feb 28, 2017) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | |
| Sales | $ 39,807 | 39,498 | 42,237 |
| Costs, Expenses and Other | |||
| Materials and production | 13,891 | 14,934 | 16,768 |
| Marketing and administrative | 9,762 | 10,313 | 11,606 |
| Research and development | 10,124 | 6,704 | 7,180 |
| Restructuring costs | 651 | 619 | 1,013 |
| Other (income) expense, net | 720 | 1,527 | (11,613) |
| Total Costs, Expenses and Other | 35,148 | 34,097 | 24,954 |
| Income Before Taxes | 4,659 | 5,401 | 17,283 |
| Taxes on Income | 718 | 942 | 5,349 |
| Net Income | 3,941 | 4,459 | 11,934 |
| Less: Net Income Attributable to Noncontrolling Interests | 21 | 17 | 14 |
| Net Income Attributable to Merck & Co., Inc. | 3,920 | 4,442 | 11,920 |
| Basic Earnings per Common Share Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) | 1.42 | 1.58 | 4.12 |
| Earnings per Common Share Assuming Dilution Attributable to Merck & Co., Inc. Common Shareholders (in dollars per share) | 1.41 | 1.56 | 4.07 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2016 | |||
Consolidated Statement of Comprehensive Income | |||
Period Ending Dec 31, 2016 10-K (Filed: Feb 28, 2017) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | |
| Net Income Attributable to Merck & Co., Inc. | $ 3,920 | 4,442 | 11,920 |
| Other Comprehensive Income (Loss) Net of Taxes: | |||
| Net unrealized (loss) gain on derivatives, net of reclassifications | (66) | (126) | 398 |
| Net unrealized (loss) gain on investments, net of reclassifications | (44) | (70) | 57 |
| Benefit plan net (loss) gain and prior service (cost) credit, net of amortization | (799) | 579 | (2,077) |
| Cumulative translation adjustment | (169) | (208) | (504) |
| Other comprehensive income (loss), net of taxes | (1,078) | 175 | (2,126) |
| Comprehensive Income Attributable to Merck & Co., Inc. | 2,842 | 4,617 | 9,794 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | |||
MERCK & CO., INC. | |||
Ticker: MRK Fiscal Year: 2016 | |||
Consolidated Statement of Cash Flows | |||
Period Ending Dec 31, 2016 10-K (Filed: Feb 28, 2017) | |||
| (In Millions, except shares in actual) | |||
| 12 Months Ended | 12 Months Ended | 12 Months Ended | |
| Dec 31, 2016 | Dec 31, 2015 | Dec 31, 2014 | |
| Cash Flows from Operating Activities | |||
| Net income | $ 3,941 | 4,459 | 11,934 |
| Adjustments to reconcile net income to net cash provided by operating activities: | |||
| Depreciation and amortization | 5,441 | 6,375 | 6,691 |
| Intangible asset impairment charges | 3,948 | 162 | 1,222 |
| Charge related to the settlement of worldwide Keytruda patent litigation | 625 | 0 | 0 |
| Foreign currency devaluation related to Venezuela | 0 | 876 | 0 |
| Net charge related to the settlement of Vioxx shareholder class action litigation | 0 | 680 | 0 |
| Gain on divestiture of Merck Consumer Care business | 0 | 0 | (11,209) |
| Gain on AstraZeneca option exercise | 0 | 0 | (741) |
| Loss on extinguishment of debt | 0 | 0 | 628 |
| Equity income from affiliates | (86) | (205) | (257) |
| Dividends and distributions from equity method affiliates | 16 | 50 | 185 |
| Deferred income taxes | (1,521) | (764) | (2,600) |
| Share-based compensation | 300 | 299 | 278 |
| Other | 313 | 874 | 34 |
| Net changes in assets and liabilities: | |||
| Accounts receivable | (619) | (480) | (554) |
| Inventories | 206 | 805 | 79 |
| Trade accounts payable | 278 | (37) | 593 |
| Accrued and other current liabilities | (2,018) | (8) | 1,635 |
| Income taxes payable | 124 | (266) | (21) |
| Noncurrent liabilities | (809) | (277) | 190 |
| Other | 237 | (5) | (98) |
| Net Cash Provided by Operating Activities | 10,376 | 12,538 | 7,989 |
| Cash Flows from Investing Activities | |||
| Capital expenditures | (1,614) | (1,283) | (1,317) |
| Purchases of securities and other investments | (15,651) | (16,681) | (24,944) |
| Proceeds from sales of securities and other investments | 14,353 | 20,413 | 15,114 |
| Divestiture of Merck Consumer Care business, net of cash divested | 0 | 0 | 13,951 |
| Dispositions of other businesses, net of cash divested | 0 | 316 | 1,169 |
| Proceeds from AstraZeneca option exercise | 0 | 0 | 419 |
| Acquisition of Cubist Pharmaceuticals, Inc., net of cash acquired | 0 | (7,598) | 0 |
| Acquisition of Idenix Pharmaceuticals, Inc., net of cash acquired | 0 | 0 | (3,700) |
| Acquisitions of other businesses, net of cash acquired | (780) | (146) | (181) |
| Acquisition of Bayer AG collaboration rights | 0 | 0 | (1,000) |
| Cash inflows from net investment hedges | 29 | 139 | 195 |
| Other | 453 | 82 | (80) |
| Net Cash Used in Investing Activities | (3,210) | (4,758) | (374) |
| Cash Flows from Financing Activities | |||
| Net change in short-term borrowings | 0 | (1,540) | (460) |
| Payments on debt | (2,386) | (2,906) | (6,617) |
| Proceeds from issuance of debt | 1,079 | 7,938 | 3,146 |
| Purchases of treasury stock | (3,434) | (4,186) | (7,703) |
| Dividends paid to stockholders | (5,124) | (5,117) | (5,170) |
| Other dividends paid | 0 | 0 | (77) |
| Proceeds from exercise of stock options | 939 | 485 | 1,560 |
| Other | (118) | (61) | 79 |
| Net Cash Used in Financing Activities | (9,044) | (5,387) | (15,242) |
| Effect of Exchange Rate Changes on Cash and Cash Equivalents | (131) | (1,310) | (553) |
| Net (Decrease) Increase in Cash and Cash Equivalents | (2,009) | 1,083 | (8,180) |
| Cash and Cash Equivalents at Beginning of Year | 8,524 | 7,441 | |
| Cash and Cash Equivalents at End of Year | 6,515 | 8,524 | 7,441 |
10-K.Info (Beta Test) Courtesy of Short Sands, LLC | ||
MERCK & CO., INC. | ||
Ticker: MRK Fiscal Year: 2016 | ||
Consolidated Balance Sheet | ||
Period Ending Dec 31, 2016 10-K (Filed: Feb 28, 2017) | ||
| (In Millions, except shares in actual) | ||
| As of | As of | |
| Dec 31, 2016 | Dec 31, 2015 | |
| Assets | ||
| Current Assets | ||
| Cash and cash equivalents | $ 6,515 | 8,524 |
| Short-term investments | 7,826 | 4,903 |
| Accounts receivable (net of allowance for doubtful accounts of $195 in 2016 and $165 in 2015) (excludes accounts receivable of $10 in 2015 classified in Other assets) | 7,018 | 6,484 |
| Inventories (excludes inventories of $1,117 in 2016 and $1,569 in 2015 classified in Other assets - see Note 6) | 4,866 | 4,700 |
| Other current assets | 4,389 | 5,140 |
| Total current assets | 30,614 | 29,751 |
| Investments | 11,416 | 13,039 |
| Property, Plant and Equipment (at cost) | ||
| Land | 412 | 490 |
| Buildings | 11,439 | 12,154 |
| Machinery, equipment and office furnishings | 14,053 | 14,261 |
| Construction in progress | 1,871 | 1,525 |
| Property, plant and equipment (at cost) | 27,775 | 28,430 |
| Less: accumulated depreciation | 15,749 | 15,923 |
| Property, plant and equipment, net | 12,026 | 12,507 |
| Goodwill | 18,162 | 17,723 |
| Other Intangibles, Net | 17,305 | 22,602 |
| Other Assets | 5,854 | 6,055 |
| Total Assets | 95,377 | 101,677 |
| Liabilities and Equity | ||
| Current Liabilities | ||
| Loans payable and current portion of long-term debt | 568 | 2,583 |
| Trade accounts payable | 2,807 | 2,533 |
| Accrued and other current liabilities | 10,274 | 11,216 |
| Income taxes payable | 2,239 | 1,560 |
| Dividends payable | 1,316 | 1,309 |
| Total current liabilities | 17,204 | 19,201 |
| Long-Term Debt | 24,274 | 23,829 |
| Deferred Income Taxes | 5,077 | 6,535 |
| Other Noncurrent Liabilities | 8,514 | 7,345 |
| Merck & Co., Inc. Stockholders Equity | ||
| Common stock, $0.50 par value Authorized - 6,500,000,000 shares Issued - 3,577,103,522 shares in 2016 and 2015 | 1,788 | 1,788 |
| Other paid-in capital | 39,939 | 40,222 |
| Retained earnings | 44,133 | 45,348 |
| Accumulated other comprehensive loss | (5,226) | (4,148) |
| Stockholders' equity before deduction for treasury stock | 80,634 | 83,210 |
| Less treasury stock, at cost: 828,372,200 shares in 2016 and 795,975,449 shares in 2015 | 40,546 | 38,534 |
| Total Merck & Co., Inc. stockholders equity | 40,088 | 44,676 |
| Noncontrolling Interests | 220 | 91 |
| Total equity | 40,308 | 44,767 |
| Total Liabilities and Equity | 95,377 | 101,677 |
| External Links | |
| MERCK & CO., INC. (MRK) Fiscal Year 2016 | |
| Statements of 10-K in Excel | https://www.sec.gov/.../Financial.xlxs |
| Complete 10-K in HTML | https://www.sec.gov/.../10-K.html |
| Complete 10-K in XBRL | https://www.sec.gov/.../10-K-xbrl.zip |